March 2019: Olanzapine has been removed from recommendation 1.6.4 because the clinical need can now be met by a licensed product. Additional information for this recommendation stated that haloperidol and olanzapine do not have UK marketing authorisation for delirium treatment. However, haloperidol does now have marketing authorisation, therefore, the additional information was removed because it no longer applies to haloperidol.
Recommendation 1.5.1 has been amended because a delirium diagnosis is now confirmed using DSM-V.
Minor changes after publication
April 2022: We amended recommendation 1.6.4 to highlight the possible risks associated with using haloperidol for the acute treatment of delirium in older people and removed the recommendation about using antipsychotic drugs with caution because haloperidol is now the only licensed product for this use.